Perakizumab
Appearance
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 03:42, 5 October 2020 (→top: HTTP → HTTPS for World Health Organization, replaced: = http://www.who.int/ → =https://www.who.int/). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:42, 5 October 2020 by Bender the Bot (talk | contribs) (→top: HTTP → HTTPS for World Health Organization, replaced: = http://www.who.int/ → =https://www.who.int/)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IL17A |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6454H9964N1718O2030S44 |
Molar mass | 145515.34 g·mol−1 |
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.[1] It binds to IL17A and acts as an immunomodulator.[2]
This drug was developed by Genentech/Roche.
References
IL-1 |
| ||||
---|---|---|---|---|---|
IL-2 | |||||
IL-3 | |||||
IL-4 |
| ||||
IL-5 |
| ||||
IL-6 |
| ||||
IL-7 |
| ||||
IL-8 |
| ||||
IL-9 |
| ||||
IL-10 |
| ||||
IL-11 |
| ||||
IL-12 |
| ||||
IL-13 |
| ||||
IL-15 |
| ||||
IL-17 |
| ||||
IL-18 |
| ||||
IL-20 |
| ||||
IL-21 |
| ||||
IL-22 |
| ||||
IL-23 |
| ||||
IL-27 |
| ||||
IL-28 | |||||
IL-31 |
| ||||
IL1RL1 |
| ||||
IL1RL2 |
| ||||
Others |
|
![]() | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles